|Dr. Roger James Pomerantz M.D., F.A.C.P.||Chairman, Pres & CEO||1.1M||N/A||1957|
|Mr. Eric D. Shaff||Exec. VP, Chief Operating & Financial Officer and Treasurer||561.92k||N/A||1976|
|Dr. John G. Aunins||CTO and Exec. VP of Bioprocess & Manufacturing||N/A||N/A||1961|
|Dr. David N. Cook||Exec. VP of R&D and Chief Scientific Officer||N/A||N/A||1958|
|Mr. Carlo Tanzi||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2018 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.